


## INFORMATION DISCLOSURE CITATION

Applicant(s)

Lerchen, et al.



## FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	S U B - CLASS	TRANSLATION	
					YES	NO
<del>F<sub>1</sub> 0 1 1 7 5 6 3</del>	<del>15/03/01</del>	<del>WO</del>	<del></del>	<del></del>	<del></del>	<del></del>
<del>F<sub>2</sub> 9 3 2 0 2 2 9</del>	<del>14/10/93</del>	<del>WO</del>	<del></del>	<del></del>	<del></del>	<del></del>

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

- ms* **R<sub>1</sub>** Kurohane, K., Namba, Y., Oku, N., "Liposomes modified with a synthetic Arg-Gly-Asp mimetic inhibit lung metastasis of B16BL6 melanoma cells", Life Sciences, 68: 273-281 (2000)
- R<sub>2</sub>** Van Waes, C., Enamorado-Ayala, I., Hecht, D., Sulica, L., Chen, Z., Batt, D. G., Mousa, S., "Effects of the novel  $\alpha v$  integrin antagonist SM256 and cis-platinum on growth of murine squamous cell carcinoma PAM LY8, International Journal of Oncology, 16: 1189-1195 (2000)
- R<sub>3</sub>** Kerr, J. S., Wexler, R. S., Mousa, S. A., Robinson, C. S., Wexler, E. J., Mohamed, S., Voss, M. E., Devenny, J. J., Czerniak, P. M., Gudzelak, A., Slee, A. M., "Novel Small Molecule  $\alpha v$  Integrin Antagonists: Comparative Anti-Cancer Efficacy with Known Angiogenesis Inhibitors", Anticancer Research, 19: 959-968 (1999)
- R<sub>4</sub>** Fields, G. B., "Integrins: Cell Adhesion Molecules in Cancer", Exp. Opin. Ther. Patents, 8(6): 633-644 (1998)
- R<sub>5</sub>** Carron, C. P., Meyer, D. M., Pegg, J. A., Engleman, V. W., Nickols, M. A., Settle, S. L., Westlin, W. F., Ruminski, P. G., and Nickols, G. A., "A Peptidomimetic Antagonist of the Integrin  $\alpha v \beta 3$  Inhibits Leydig Cell Tumor Growth and the Development of Hypercalcemia of Malignancy", Cancer Research, 58: 1930-1935 (May 1998)
- R<sub>6</sub>** Brooks, P. C., Clark, R. A. F., Cheresh, D. A., "Requirement of Vascular Integrin  $\alpha v \beta 3$ ", Science, 264: 569-571 (April 1994)
- R<sub>7</sub>** Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., Cheresh, D. A., "Integrin  $\alpha v \beta 3$  Antagonists Promotes Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels", Cell, 79: 157-1164 (Dec. 1994)
- R<sub>8</sub>** Varner, J. A., Cheresh, D. A., "Tumor Angiogenesis and the Role of Vascular Cell Integrin  $\alpha v \beta 3$ ", Important Advances in Oncology, pp. 69-87 (1996)
- R<sub>9</sub>** Varner, J. A., Cheresh, D. A., "Integrins and Cancer", Current Opinion in Cell Biology, 8: 724-730 (1996)
- R<sub>10</sub>** Varner, J. A., Brooks, P. C., Cheresh, D. A., "Review: The Integrin  $\alpha v \beta$ : Angiogenesis and Apoptosis", Cell Adhesion and Communication, 3: 367-374 (1995)
- R<sub>11</sub>** Gasparini, G., "The Rationale and Future Potential of Angiogenesis Inhibitors in Neoplasma", Drugs, 58(1): 17-38 (Jul. 1999)
- R<sub>12</sub>** Damiano, J. S., Cress, A. E., Hazehurst, L. A., Shtil, A. A., Dalton, W. S., "Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines", Blood, 93(5): 1658-1667 (March 1999)

EXAMINER

DATE CONSIDERED


\* EXAMINER: Initial if citation considered. whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant(s)

Lerchen, et al.

INFORMATION DISCLOSURE CITATION

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)



R<sub>13</sub>

Uhm, J. H., Dooley, N. P., Kyritsis, A. P., Rao, J. S., Gladson, C. L., "Vitronectin, g Glioma-derived Extracellular Matrix Protein, Protects Tumor Cells from Apoptotic Death", Clinical Cancer Research, 5: 1587-1594 (June 1999)

R<sub>14</sub>

Mueller, B. M., Reisfeld, R. A., Silveira, M. H., Duncan, J. D., Wrasidlo, W. A., "Pre-Clinical Therapy of Human Melanoma with Morpholino-Doxorubicin Conjugated to a Monoclonal Antibody Directed Against an Integrin on Melanoma Cells", Antibody Immunoconjugates and Radiopharmaceuticals, 4(2): 99-106 (Nov. 1991)

R<sub>15</sub>

Van Hagen, P. M., Breeman, W. A. P., Bernard, H. F., Schaar, M., Mooij, C. M., Srinivasan, A., Schmidt, M. A., Krenning, F. P., De Jong, M., "Evaluation of a Radiolabelled Cyclic DTPA-RGD Analogue for Tumour Imaging and Radionuclide Therapy", Int. J. Cancer, 8: 186-198 (2000)

R<sub>16</sub>

Bitan, G. Scheibler, L., Greenberg, Z., Rosenblat, M., Chorev, M., "Mapping the Integrin  $\alpha v \beta 3$ -Ligand Interface by Photoaffinity Cross-Linking", Biochemistry, 38: 3414-3420 (1999)

R<sub>17</sub>

Sheu, J. R., Lin, C. H., Peng, H. C., Huang, T. F., "Triflavin, an Arg-Gly-Asp-Containing Peptide, Inhibits the Adhesion of Tumor Cells to Matrix Proteins via Binding to Multiple Integrin Receptors Expressed on Human Hepatoma Cells", Proc. Soc. Exp. Biol. Med., 213(1): 71-79 (1996)

R<sub>18</sub>

Kim, J.-W., Yoon, J.-H., Lee, H.-S., Kim, C.-Y., "Vasculature Targeted Chemotherapy: Effect of Integrin AV Homing Peptide-Doxorubicin Conjugate on the Growth of Experimental Hepatoma", Gastroenterology, 118(4), page AASLD A907, Abstract No. 52 (April 2000)

R<sub>19</sub>

Mizejewski, G. J., "Role of Integrins in Cancer: Survey of Expression Patterns", Proc. Soc. Exp. Biol. Med., 222(2): 124-138 (Nov. 1999)

R<sub>20</sub>

Nickols, A., Westlin, W., Meyer, D., Pegg, J., Engleman, W., Ruminski, P., Nickols, M., Settle, S., Carron, C., "Antiangiogenic and Anticancer Activities of Antagonists of Integrin  $\alpha v \beta 3$ ", Proc. Annu. Meet. AACR, 38: 206, Abstract No. 1389 (March 1997)

R<sub>21</sub>

MacDonald, T. J., Laug, W. E., "Migration of Human Brain Tumor Cells and Human Brain Endothelial Cells on Tenascin Requires the Integrin  $\alpha v \beta 3$ : A Unifying Model for Brain Tumor Invasion and Angiogenesis", Proc. Annu. Meet. AACR, 39: 497, Abstract No. 3382 (March 1998)

EXAMINER

DATE CONSIDERED

2/20/03

\* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.